Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 16/20 | 0.59 |
| ▸ | CDK7 | P50613 | 3/20 | 0.53 |
| ▸ | ABL1 | P00519 | 1/20 | 0.53 |
| ▸ | LCK | P06239 | 1/20 | 0.53 |
| ▸ | CSF1R | P07333 | 1/20 | 0.53 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.53 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.53 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6180720 | 0.80 | KDR (0.66) | KDRCDK7ABL1LCKCSF1R | |
| SCHEMBL6180700 | 0.79 | KDR (0.65) | KDRCDK7ABL1LCKCSF1R | |
| SCHEMBL27584823 | 0.76 | KDR (0.61) | KDRCDK7ABL1LCKCSF1R | |
| SCHEMBL14469653 | 0.75 | CASR (0.56) | — | |
| SCHEMBL7237397 | 0.75 | KDR (1.00) | KDRCDK7ABL1LCKCSF1R | |
| SCHEMBL7235425 | 0.74 | KDR (0.52) | KDRCDK7ABL1LCKCSF1R | |
| SCHEMBL7237670 | 0.74 | KDR (0.69) | KDRCDK7ABL1LCKCSF1R | |
| SCHEMBL7228017 | 0.73 | KDR (0.60) | KDRCDK7ABL1LCKCSF1R | |
| SCHEMBL6180146 | 0.73 | KDR (0.67) | KDRCDK7ABL1LCKCSF1R | |
| SCHEMBL15641495 | 0.72 | KDR (0.52) | KDRCDK7ABL1LCKCSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6586424-B2 | Anticancer agents; anticholesterol agents | MERCK & CO., INC. | 2003-07-01 | — | — | US | disclosed |
| US-6586423-B2 | 2-(Pyridin-2-ylamino)-thiazole-5-carbonitrile derivatives; angiogenesis inhibitors; antitumor and anticarcinogenic agents; atherosclerosis, macular degeneration, diabetic retinopathy | MERCK & CO., INC. | 2003-07-01 | — | — | US | disclosed |